EGFR and neoplasm: The sample size treated thus far is small, with six patients, and the follow‐up duration is relatively low, but the overall phenotype is a reduction in the tumor sizes, so confirmation with more patients and longer follow‐up is needed.[400] Another study demonstrated that directly incorporating cetuximab into CAR‐T cells using a lentiviral vector can effectively target EGFR‐positive cancer cells with high specificity.